ライフサイエンスコーパス: revaccination

1 No safety concerns were raised with IIV-HD revaccination.

2 ty concerns emerged in the context of IIV-HD revaccination.

3 ses, which remained elevated up to 1 y after revaccination.

4 butes of lymphocyte responses boosted by BCG revaccination.

5 memory B cells recognizing that strain upon revaccination.

6 me to revaccination predicted nonresponse to revaccination.

7 n developed protective antibody levels after revaccination.

8 wever, 18 of 19 children seroconverted after revaccination.

9 acy of either vaccine would be affected upon revaccination.

10 revaccination and 365 (171,293 children) no revaccination.

11 time, autoantibody levels were boosted upon revaccination.

12 o mount a robust anamnestic Ab response upon revaccination.

13 antibody titers were measured 8 weeks' post revaccination.

14 h IPT modulates BCG immunogenicity following revaccination.

15 Nonresponders will not benefit from revaccination.

16 either PN23 primary vaccination (n = 60) or revaccination 3-5 years after receiving a first PN23 vac

17 rapy (HAART), exposure to measles virus, and revaccination among children infected with human immunod

18 schools (176,846 children) were assigned BCG revaccination and 365 (171,293 children) no revaccinatio

19 erent after primary vaccination versus after revaccination and indicates that memory can exist in ind

20 en seroconverted during the outbreak without revaccination and were likely exposed to wild-type measl

21 and CD3(-)CD56(hi) NK cells at baseline, BCG revaccination boosted these responses, which remained el

22 robust neutralizing antibody responses upon revaccination, but the role CD4(+) T cells play in this

23 te reactions occur more frequently following revaccination compared with first vaccination; however,

24 ined on day 0 (before primary vaccination or revaccination), day 30, day 60, and annually during year

25 We studied revaccination efficacy in two Brazilian cities with tube

26 ded to assess the effect of other factors on revaccination efficacy: time since vaccination, age at v

27 g effectiveness supports the need for annual revaccination, even in the absence of antigenic drift in

28 influenza and pneumococcal vaccination with revaccination for patients age >65 years who are taking

29 Lack of evidence about the effectiveness of revaccination for people 65 years of age or older, when

30 itial nonresponders, 88 (86.3%) responded to revaccination, for an overall response, including to rev

31 Revaccination given to children aged 7-14 years in this

32 the protection against tuberculosis from BCG revaccination in school-aged children who had had one BC

33 monitoring of antibody levels and timing of revaccination in these patients.

34 Measles revaccination induced high rates of seroprotection and m

35 By day 30, both primary vaccination and revaccination induced significant increases in opsonic a

36 However, revaccination-induced titer increases were only about 2-

37 he age of 65, has limited effectiveness, and revaccination induces attenuated antibody responses.

38 ation at 6 months of age followed by routine revaccination is recommended when exposure of infants to

39 Revaccination may renew protection.

40 ble to diphtheria (e.g., adults) rather than revaccination of children.

41 Revaccination of CRM-OS recipients with PS at 2 months d

42 The risk of adverse events associated with revaccination of elderly and chronically ill persons 5 o

43 Revaccination of healthy adults with pneumococcal polysa

44 Timely revaccination of HIV-1-infected nonresponders increased

45 This study shows that revaccination of low-responding HCWs with the pH1N1 vacc

46 Revaccination of older adults with PN23 was comparable t

47 Gs and to ensure consistent product release, revaccination of plasma donors was investigated as a mea

48 majority of these cases being preventable by revaccination of previously vaccinated persons.

49 ation, for an overall response, including to revaccination, of 94.9%.

50 ted to characterize the effects of HAART and revaccination on measles immunoglobulin G (IgG) serostat

51 y vs. postnatal delivery) and the benefit of revaccination over the course of multiple pregnancies.

52 ion against smallpox during the postexposure revaccination period may require T cell memory as an ess

53 plasma HIV-1 RNA levels, and longer time to revaccination predicted nonresponse to revaccination.

54 BCG vaccination is routine in Brazil but BCG revaccination procedures vary by state.

55 uring years 2-5 after primary vaccination or revaccination remained higher than in vaccine-naive pers

56 ccine-associated adverse events, the 10-year revaccination schedule has come into question.

57 Revaccination status was masked during linkage and valid

58 effectiveness of HZ vaccine suggests that a revaccination strategy may be needed, if feasible.

59 work supports development of MTBVAC use as a revaccination strategy to improve on the effects of BCG

60 ody levels tended to be modestly lower after revaccination, study groups had similar GMCs at later ti

61 concentrations (GMCs) of IgG were higher in revaccination than primary vaccination subjects.

62 Ten days after revaccination, the conjugate and IPV groups had similar

63 One week following revaccination, those given 2 doses of PsA-TT had the gre

64 Before revaccination, titers were higher in the conjugate and M

65 Revaccination transiently boosted BCG-specific Th1 cytok

66 The efficacy of BCG revaccination was 9% (-16 to 29%).

67 y, neutralizing antibody responses following revaccination were significantly higher in individuals w

68 Day 30 levels following revaccination were slightly lower but not significantly

69 We compared revaccination with 23-valent pneumococcal polysaccharide

70 els for 5 years after primary vaccination or revaccination with 23-valent pneumococcal polysaccharide

71 Among HIV-infected low-level responders, revaccination with a double dose of pneumococcal vaccine

72 e of HIV-1-infected initial nonresponders to revaccination with a standard HBV vaccine series.

73 of isoniazid preventive therapy (IPT) before revaccination with bacillus Calmette-Guerin (BCG) in hea

74 exposure tuberculosis vaccination, including revaccination with BCG, might benefit Mtb-uninfected HCW

75 cal trial, we compared the immunogenicity of revaccination with PCV ( n = 131) or PPV (n = 73) among

76 Among persons with HIV infection, revaccination with PCV was only transiently more immunog

77 Both primary vaccination and revaccination with PN23 induce antibody responses that p

78 Primary vaccination or revaccination with PN23 induced significant increases in

79 Based on our results, revaccination with pneumococcal vaccines after transplan

80 isk does not represent a contraindication to revaccination with PPV for recommended groups.

81 disease persists, and antibody responses to revaccination with the 23-valent polysaccharide vaccine

82 We determined whether revaccination with the 7-valent pneumococcal conjugate v

83 Revaccination with the pH1N1 vaccine elicited rapid HI a

84 of an antigen to allow antibody responses on revaccination) with vaccine directed toward an older avi

85 mained high and few became carriers, booster revaccination within 10 years seems unnecessary.

86 vation in smallpox outbreaks that successful revaccination within 4 days of exposure is partially pro